Analystreport

Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Mizuho from $6.66 to $3.10. They now have a "neutral" rating on the stock.

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com